Clinical Study on Endoscopic Management of GOV1 Esophagogastric Varices

Status Not yet recruiting

Clinical Trial Summary

The patients with GOV1 esophagogastric varices will be treated with gastric variceal tissue gel injection, at the same time, the esophageal varices were treated with ligation, sclerotherapy, or no treatment. A new method for the treatment of esophageal varices will be proposed to improve the effective rate and reduce the recurrence rates and mortality, shorter hospital stays, and lower treatment costs, while further expanding HVPG testing to develop the best strategy for secondary prevention of endoscopic treatment in patients with GOV1 type esophageal and gastric varices.

Clinical Trial Description

Cirrhotic portal hypertension can cause esophageal and gastric varices, and esophageal and gastric varices bleeding (EGVB) were associated with portal vein pressure. At present, the gold standard for detecting portal pressure in clinical practice is hepatic venous pressure gradient (HVPG). For Sarin classification GOV1 of esophagogastric varices are from a single origin, the left gastric vein. If the fundus varicose veins receive complete embolization treatment, the esophageal variceal blood flow should be completely blocked, and such patients do not need to perform esophageal surgery. However, this has not been reported in the literature. Patients with esophageal and gastric varices identified by CT as GOV1 will be enrolled, all of whom will receive HVPG detects. The patients were randomly divided into three groups. The patients in group A will receive endoscopic gel embolization for gastric varices and esophageal varices ligation treatment, group B patients will receive endoscopic gastric variceal tissue glue embolization and esophageal variceal sclerotherapy treatment, the patients in group C will receive endoscopic gelatinization of gastric fundus varices (esophageal varices were not treated). Patients in the three groups were followed up with CTP and gastroscopy 1 month, 3 months, and 6 months after the initial treatment, and additional endoscopic treatment will be provided if necessary. If bleeding occurs again during this period, timely treatment (medication, endoscopy, intervention or surgery) is required according to the condition. A new method for the treatment of esophageal varices will be proposed to improve the effective rate and reduce the recurrence rates and mortality, shorter hospital stays, and lower treatment costs, while further expanding HVPG testing to develop the best strategy for secondary prevention of endoscopic treatment in patients with GOV1 type esophageal and gastric varices. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05978752
Study type	Interventional
Source	Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact	Hongxia Li, Doctor
Phone	+8618252006898
Email	lhx100918@163.com
Status	Not yet recruiting
Phase	N/A
Start date	December 2023
Completion date	November 2025

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05055713` - A Randomized Controlled Study on the Treatment of Cirrhosis Combined With Hypersplenism	N/A
Recruiting	`NCT02945930` - Study the Safety and Efficacy of "Compont Medical Glue" in the Treatment of Esophagogastric Varices	N/A
Completed	`NCT04823780` - The Effects of Early Enteral Nutrition on Endoscopic Therapy of Esophagogastric Varices in Liver Cirrhosis
Completed	`NCT03244332` - HEMOCC Study. Hemostasis in Cirrhotic Children.	N/A
Completed	`NCT02991612` - Rifaximin in Patients With Gastroesophageal Variceal Bleeding	N/A
Recruiting	`NCT02964195` - Efficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal Bleeding	N/A
Completed	`NCT00004641` - A Study to Prevent Complications of High Blood Pressure Caused by Hepatitis in Patients With Cirrhosis	Phase 2
Completed	`NCT02593799` - Non-invasive Prediction of Esophageal Varices in Liver Cirrhosis: A Multicenter Observational Study
Recruiting	`NCT02719119` - Trial of Monthly Versus Bi-weekly Endoscopic Variceal Ligation for the Prevention of Esophageal Variceal Rebleeding	N/A
Recruiting	`NCT02385422` - The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding	Phase 4
Completed	`NCT00838864` - Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis for Variceal Bleeding	Phase 4
Not yet recruiting	`NCT03130127` - Continuous Versus Bolus Infusion of Terlipressin for Portal Hypertension Related Bleeding in Liver Cirrhosis	N/A
Active, not recruiting	`NCT05979935` - Prediction of Esophageal Varices in Liver Cirrhosis Using Tongue Bioinformatics
Recruiting	`NCT02504723` - Carvedilol as an Adjunct to Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding	Phase 4
Withdrawn	`NCT00475592` - Validation of Esophageal Variceal Grading: A Comparative Study of Upper Gastrointestinal (GI) Endoscopy and Capsule Endoscopy	N/A
Completed	`NCT05331768` - Comparison of Endoscopic Band Ligation Plus 24-hour Versus 72-hour Terlipressin Therapy	N/A
Completed	`NCT04210297` - Development and Validation of an Noninvasive Model for Predicting High Risk Esophageal Varices in Cirrhosis
Recruiting	`NCT02311608` - Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails	N/A
Completed	`NCT04976543` - Safety of Anticoagulant Therapy After Endoscopic Treatment	Phase 4
Recruiting	`NCT02695732` - The Effect of Carvedilol VS Endoscopic Therapy in Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding	Phase 4